GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome

Ina-Beate Wanner1, Julia Halford2, Jonathan Lopez2

  • 1Semel Institute for Neuroscience and Human Behavior, Intellectual and Developmental Disability Center (IDDRC), Brain Injury Research Center (BIRC), David Geffen School of Medicine, UCLA, 635 Charles E. Young Drive South, NRB315, Los Angeles, CA, 90095, USA. IWanner@mednet.ucla.edu.

Abstract

No abstract available in PubMed .